Molecular Imaging of Myocardial and Vascular Disorders With Ultrasound  by Lindner, Jonathan R.
M
V
J
P
M
o
c
t
e
o
p
u
n
a
r
t
O
T
c
b
c
i
i
t
i
f
n
a
b
i
p
a
s
F
M
M
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 3 , N O . 2 , 2 0 1 0
© 2 0 1 0 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / 1 0 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c m g . 2 0 0 9 . 0 9 . 0 2 1olecular Imaging of Myocardial and
ascular Disorders With Ultrasound
onathan R. Lindner, MD
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ethods for noninvasive imaging of specific disease-related molecular changes are being developed in
rder to expand and improve diagnostic capabilities and to enhance therapeutic decision making in the
linical setting. Thesenew techniqueshave also started tobe incorporated into researchprograms inorder
o better characterize pathophysiology or evaluate treatment efficacy. Molecular imaging with contrast-
nhanced ultrasound relies on the detection of the acoustic signal produced by either microbubbles or
ther acoustically active particulate agents that are targeted to sites of disease. This review describes the
rogress that has been made in the development and testing of methods for contrast ultrasound molec-
lar imaging of cardiovascular disease. Specifically, topics that will be addressed include: 1) the bioengi-
eering and detection schemes for targeted probes; 2) specific disease processes (myocardial ischemia,
therosclerosis, and transplant rejection) where molecular imaging may play a role; and 3) the potential
ole of ultrasound as a molecular imaging technique. (J Am Coll Cardiol Img 2010;3:204–11) © 2010 by
he American College of Cardiology Foundationp
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Scverview of Molecular Imaging
he term molecular imaging has been
used to describe a broad family of
imaging techniques used in the basic
science and clinical settings. For the
linician, the term refers to methods that have
een developed to evaluate pathophysiologic
hanges at the molecular level in vivo with med-
cal imaging techniques and usually the admin-
stration of a targeted contrast agent that binds
o or is activated by a pathologic molecule of
nterest. It is likely that this technology will
urther enhance the already indispensable role
oninvasive imaging already plays in the man-
gement of patients with cardiovascular disease
y improving diagnostic performance or allow-
ng early detection of disease. Profiling disease
henotype could also be used to select the most
ppropriate treatment therapy based on the
pecific pathway activation. This notion is
rom the Division of Cardiovascular Medicine, Oregon Health &
D, served as Guest Editor for this article.anuscript received May 27, 2009; revised manuscript received Augusrobably more familiar to those in cancer
edicine where chemotherapeutic or antian-
iogenic regimens are starting to be matched to
he molecular patterns on imaging or pathol-
gy. It should also be mentioned that molecular
maging techniques could be used to evaluate
ew therapies and whether they justify further
evelopment in the pre-clinical or clinical
tage.
The translation of molecular imaging tech-
ology to patients relies on matching the tar-
eted probes to the clinical purpose. For exam-
le, early detection of atherosclerosis will
equire targeting of the sentinel events of ath-
rosclerosis such as the presence of oxidized
ipoproteins in the vessel wall or endothelial
ell activation; whereas risk assessment in those
ith more established disease will likely require
robes that can evaluate macrophage content,
rotease activity, apoptosis, or prothrombotic
ilieu. It is, therefore, not surprising that a
ience University, Portland, Oregon. Sanjiv Kaul,t 21, 2009, accepted September 17, 2009.
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205yriad of different targets involved in atherosclero-
is, ischemia, and angiogenesis have been explored
n pre-clinical studies. It should also be mentioned
hat the imaging technique must also be matched to
linical purpose in terms of sensitivity, spatial res-
lution, and practical issues of cost and ease of use.
This review will focus on one form of molecular
maging, targeted contrast-enhanced ultrasound
CEU). This technique relies on the selective tar-
eting and retention of microbubbles or acoustically
ctive nanoparticles at sites of disease. These agents
re generally confined to the vascular space except
n situations of extraordinary vascular injury. For
valuation of myocardial and vascular diseases, tar-
eted ultrasound probes have generally been used to
valuate endothelial phenotype or activation and
dhesion of immune cells. Contrast agents that are
argeted to thrombus or for use in gene/drug
elivery have also been developed but will not be
overed in this review.
ioengineering of Targeted Ultrasound
ontrast Probes
icrobubble and submicrometer ultrasound con-
rast agents generally have a stabilizing polymer or
lbumin “shell” or a surfactant layer in the case of
ipid-stabilized agents. Encapsulation enhances in
ivo stability of microbubble contrast agents by
educing surface tension and preventing outward
iffusion of the gas core component (1). For the
urposes of molecular targeting, the shell also serves
s the interface between the gas bubble and the
iologic microenvironment.
A simple strategy for microbubble targeting has
een to seize upon the ability of the innate immune
ystem to recognize and remove foreign particles.
icrobubbles with either lipid or albumin surfaces
an activate serum complement locally at the bub-
le–blood interface (2–4). Activated complement
omponents such as C3b on the microbubble sur-
ace mediate interactions between microbubbles
nd activated leukocytes. These interactions have
een used to image acute and severe cellular inflam-
atory responses in acute myocardial infarction,
evere chronic ischemic left ventricular dysfunction,
nd transplant rejection (Fig. 1) (5–7). Comple-
ent can also mediate interactions between endo-
helial cells and microbubbles with either albumin
r lipid shell (4,8,9). This interaction provides a
imple method for detecting chronic or acute en-
othelial activation in animal models of atheroscle- losis and vascular injury (4,9). For lipid micro-
ubbles, the sensitivity for detecting leukocyte ac-
ivation and cellular adhesion can be increased by
he addition of lipids that carry a strong net nega-
ive charge thereby amplifying complement activa-
ion, or by eliminating the polyethyleneglycol sur-
actant layer that creates a steric boundary (8).
A more specific and more efficient targeting
pproach has been to conjugate ligands against
isease-related molecules to the surface of contrast
gents. Examples of the type of ligands include
onoclonal antibodies (mAb), peptides, glyco-
roteins, and peptidomimetic small molecules. The
ost common strategy has been to conjugate these
igands to a bifunctional molecule that has a lipid
embrane anchor domain (e.g., hydrophobic poly-
arbon tail) and also a molecular spacer that projects
he ligand away from the shell surface.
The attachment of multivalent micro- or
anoscale contrast agents to disease molecules de-
ends on host-related factors (site, den-
ity, and location of the target molecule;
resence of endogenous inhibitors; shear
orces) as well as bubble-related factors.
or the latter, the surface density of li-
ands is an important issue that in flow
hamber experiments tends to affect bind-
ng efficiency at medium to high shear
ates (Fig. 2A) (10). Based on the data
hat have been generated for lipid micro-
ubbles, most targeted imaging protocols
n vivo are performed with agents that
ontain several thousand ligands per
quare micrometer of shell surface area. Similarly,
he site density of the target molecule tends to affect
inding capacity of microbubbles (Fig. 2B) (11).
Ideally, the kinetic properties of the ligand that is
sed to target ultrasound contrast agents needs to
e matched to the intended microenvironment. For
xample, ligands with a rapid on-rate, such as those
rom catch bonds, may be advantageous for initiat-
ng interaction at high shear, whereas in certain
ircumstances firm attachment may be best
chieved through low “off-rate” bonds such as those
ediated by mAb. Hence, bioengineering of mi-
robubbles must be performed with the vascular
onditions in mind. Recent data have suggested
hat a dual ligand approach could be advanta-
eous for high shear binding where, similar to
eukocytes and platelets, a fast on-rate ligand
llows initial interaction with the vascular inter-
ace with subsequent formation of bonds with a
A B B
A N D
CEU
ultras
ECAM
adhes
ICAM
molec
mAb
VCAM
adhesow off-rate ligand (12).R E V I A T I O N S
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206etection of Infarction and Acute Ischemia
he diagnosis of acute coronary syndromes cur-
ently relies on combining clinical information with
idely available diagnostic tests such as electrocar-
iogram and serologic markers of myocellular ne-
rosis such as troponins. Because of the well-
ecognized limitations in the diagnostic accuracy of
his approach (13,14), newer methods for rapid
iagnosis of ischemia and/or infarction are being
eveloped. Targeted imaging of the molecular sig-
ature of ischemic injury could be used not only for
iagnosis, but also to map the spatial extent of
nvolvement, which can be important for guiding
herapy or assessing prognosis. Advantages of an
ltrasound approach include the ability to perform
edside testing and the speed of the imaging
rotocols.
Complement-mediated microbubble–leukocyte
nteractions described earlier have been used to
etect ischemic injury severe enough to produce
nfarction (4). There are several caveats to this
pproach. First, the region of enhancement with
eukocyte-targeted microbubbles in myocardial in-
arction is time-dependant because of the dynamic
patial pattern of immune cell recruitment. Hence,
he distribution of leukocyte-targeted signal tends
ograft Isograft
rdiac Allograft Rejection
ltrasound images (top) of the myocardium in the short-axis plane
ement from retained anionic microbubbles in the strain-mis-
not in an isograft. Immunohistochemistry detected robust CD-3–
te in the allograft, including intravascular cellular recruitment
permission, from Kondo et al. (7).o encompass the entire risk area early (90 min) sfter reperfused myocardial infarction, but then
radually contracts to the region of infarction (4). A
econd consideration is that leukocyte targeting is
nreliable in regions of microvascular no-reflow
here microbubble flux is absent.
The sensitivity of the leukocyte-targeted imaging
pproach has been insufficient for diagnosing isch-
mia that is mild and does not produce infarction.
his situation has required the creation of micro-
ubble probes capable of detecting modest endo-
helial activation. For this purpose, microbubbles
ave been targeted to endothelial selectins (P-
electin, E-selectin). P-selectin is stored pre-formed
n endothelial cell, is externalized within minutes of
ven mild injury or ischemia, and can persist for
ours after ischemic insult (15,16). Hence, it is an
deal target for detecting myocardial ischemia that
s ongoing or has resolved. P-selectin–targeted im-
ging was first described in renal ischemia-
eperfusion injury (17). It has since been used to
etect and spatially define recent myocardial isch-
mia in mice and rats (18,19). Targeting has been
chieved through the use of mAb, or glycoprotein
r carboydrate mimetics of the endogenous
-selectin glycoprotein ligand-1 (PSGL-1). The
onantibody targeting techniques have the theo-
etic advantage of binding to E-selectin as well,
hich could extend the window in which post-
schemic injury can be detected.
arly Detection of Atherosclerosis
t is now widely accepted that atherosclerotic lesion
everity in terms of luminal encroachment or plaque
olume (taking into account eccentric remodeling)
oes not provide a complete assessment of risk.
laque composition is a key feature for predicting
dverse events (20). Molecular imaging can provide
nsight and prognostic information on the biologic
rocesses that lead to unstable plaque growth or
cute atherothombotic events. Most ultrasound
ontrast agents do not have access to high-risk
ellular features or molecular profile of the in-
raplaque environment unless there is drastic alter-
tion of local vascular permeability (21). Hence,
EU molecular imaging of atherosclerosis has fo-
used on detection of endothelial cell activation on
he plaque surface or in the underlying vasa vaso-
um; or detection of a prothrombotic environment.
ndothelial cell adhesion molecules (ECAMs) such
s vascular cell adhesion molecule-1 (VCAM-1),
ntercellular adhesion molecule-1 (ICAM-1), orAll
Figure 1. Imaging Ca
Color-coded contrast u
showing signal enhanc
matched allograft, but
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207ritical for the initiation of atherosclerosis and are a
ajor determinant of plaque instability (22–24).
argeted imaging of ICAM-1 and VCAM-1 in
iniswine models of atheroma produced by vascu-
ar mechanical injury and cholesterol-rich diet has
een achieved with intra-arterial injection of immu-
oliposomes that are rendered echogenic by manu-
acturing processes that promote air entrapment
Fig. 3A) (25). More recently, different degrees of
laque inflammatory burden produced by dietary
anipulation in apolipoprotein-E/ mice had
een discerned by CEU detection of endothelial
CAM-1 up-regulation after intravenous adminis-
ration of targeted microbubbles (Fig. 3B) (26).
here is minimal vasa vasorum component of
isease in this murine model, indicating that endo-
helial attachment of targeted microbubbles is pos-
ible even in the face of very high shear stress of the
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Figure 2. Determinants of Targeted Microbubble Attachment in
(A) Adherence of intercellular adhesion molecule-1 (ICAM-1)–target
illustrating increasing attachment according to surface density of an
(10). (B) Adherence of P-selectin–targeted microbubbles over time t
square micrometer). Reprinted, with permission, from Takalkar et alurine aorta. Flow chamber studies suggested that uhis was possible because of the pulsatile nature of
ow in large vessels and the ability for agent to
dhere during low-shear diastolic periods (26).
ecent studies have demonstrated that molecular
maging of endothelial activation with VCAM-1
nd P-selectin–targeted microbubbles can detect
ery early atherosclerotic changes even before there
s lumen encroachment (27).
Targets other than ECAMs could be used to
valuate high-risk plaque phenotype with CEU.
chogenic perfluorocarbon nanoparticles targeted
o tissue factor have been shown to enhance the pig
arotid arteries after overstretch injury (21). It is not
urrently known whether plaque permeability for
his agent is sufficient for a tissue factor targeting
pproach in the absence of physical trauma.
omplement-mediated attachment of albumin mi-
robubbles to the vascular endothelium has been
0% 50% 75% 100%
 Antibody
0
3
Blocked
7
109
1 min
-Shear Flow Chamber Experiments
icrobubbles to quiescent or IL-1–activated endothelial cells (ECs)
CAM-1 antibody. Reprinted, with permission, from Weller et al.
ifferent site densities of plated P-selectin (3, 7, 109 molecules per
).1
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208ystem associated with vascular injury or severe
therosclerosis (4,8). There is also promise that
argeted microbubbles may be able to detect
roliferation of the vasa vasorum and plaque
eovascularization with agents targeted to adhe-
ion molecules or to endothelial epitopes with
elative specificity angiogenic vessels. However,
his phenomenon has not yet been definitively
hown.
eart Transplant Rejection
onventional methods for detecting cardiac allo-
raft rejection with noninvasive imaging are
ased on myocardial function. This approach is
omewhat insensitive for detecting rejection in
he early stages or in those with pre-existing
ysfunction. There have been few advances in
chocardiographic screening for rejection apart
rom using more sensitive strain- or tissue veloci-
y–based methods for evaluating function. The
bility to target the cellular immune response
uring heart transplant rejection is a promising
pplication for CEU molecular imaging.
omplement-mediated interactions between ac-
ivated leukocytes and anionic microbubbles have
een shown to detect heterotopic heart transplant
n a rat model of strain mismatch and to assess
he response to immunomodulatory therapy (7).
Figure 3. Molecular Imaging of Atherosclerosis
(A) Immunohistochemistry demonstrating ICAM-1 expression in the
after balloon injury, and intravascular ultrasound (IVUS) after arteria
panel) immunoliposomes. Vessel wall enhancement (arrows) was se
from Hamilton et al. (25). (B) Immunohistochemistry demonstrating
diet, high-frequency (40 MHz) ultrasound of the aortic arch in long
imaging (right panel) 10 min after intravenous injection of VCAM-1
Reprinted, with permission, from Kaufmann et al. (26).n a similar rat model, microbubbles targeted to wCAM-1 have been used to detect endothelial
ctivation in acute rejection of cardiac hetero-
rafts (21). Implicit in these results is that CEU
olecular imaging could also be useful for eval-
ating patients with suspected acute myocarditis.
maging Vascular Adaptation to Ischemia
EU molecular imaging has been used to detect
ome of the key biologic processes involved in
asculogenesis and arteriogenesis. It is difficult to
rgue that there is currently a clinical demand for
angiogenesis imaging” in ischemic heart or limb
isease. However, the pairing of CEU molecular
maging and perfusion imaging has been used as a
ool to study vascular adaptation to chronic isch-
mia and to evaluate potential treatment strategies.
t may also be useful in atherosclerotic disease for
etecting vasa vasorum remodeling which is an
mportant determinant of inflammatory burden and
isk (28).
Molecular imaging of vascular remodeling in
schemic limb models has been performed with
icrobubbles targeted against endothelial integrins
alphav-integrins) that are thought to be involved in
igration, adhesion, and survival signaling (29). In
hese studies, signal enhancement from micro-
ubbles bearing the alphav-integrin ligand echista-
in tended to herald changes in flow, particularly
oral artery of a cholesterol-fed Yucatan miniswine several weeks
ection of control (middle panel) and ICAM-1–targeted (right
only for the ICAM-1–targeted probe. Reprinted, with permission,
M-1 expression in an apolipoprotein E/ mouse on high-fat
demonstrating mural thickening (middle panel), and molecular
geted microbubbles (color scale at bottom). Ao  aorta.fem
l inj
en
VCA
axis
–tarith growth factor stimulated arteriogenesis. Vas-
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209ular remodeling can also be detected by targeting
icrobubbles directly to growth factor receptors,
uch as VEGFR-2 expressed during vasculogenesis
nd angiogenesis, although experience has been
imited mostly to tumor rather than ischemic mod-
ls (30). CEU molecular imaging of leukocyte
ctivation, monocyte recruitment, and up-
egulation of ECAMs has been used to characterize
ifferent components of the immune response that
re requisite in vasculogenesis and ischemia-
ediated angiogenesis (Fig. 4) (31). Evaluating the
nflammatory response in angiogenesis may pro-
ide an important tool for understanding and
ptimizing proangiogenic cytokine/chemokine
herapy that may have an immunomodulatory
ode of action (32).
dvantages and Limitations to the Technique
here are several relative advantages of using a
ontrast ultrasound-based approach for molecular
maging in both the clinical and research settings.
ome of the most pertinent advantages are practical
ssues such as cost, speed, and ease of use. The
echnique does not require any specialized imaging
quipment, and the protocols can be completed in
nly 8 to 10 min. The short duration of the
rotocols, short circulating half-life, and the ability
Figure 4. Targeted Imaging of Monocyte Recruitment in Ischem
Images at the top illustrate a B-mode image and color-coded ultras
mal hindlimb of a mouse 2 days after iliac artery ligation. Immunoh
inﬁltration. Quantitative data illustrate selective signal enhancemen
persists for several days after iliac artery ligation. Adapted, with permisso destroy the contrast agent after image acquisition
rovides the opportunity to perform sequential
njections. This is a key issue that allows one to
emporally characterize expression profile and to
mage several different molecular targets during a
ingle relatively brief imaging period. The ability to
lmost simultaneously acquire structural and/or
unctional information together with molecular sig-
al is also an advantage of an ultrasound-based
pproach.
There are also important limitations for CEU
olecular imaging. First and foremost is the
nability to target events that occur outside of the
ascular compartment. Hence, it is unable to
valuate certain processes that are important in
ardiovascular disease such as matrix remodeling,
ellular apoptosis, and oxidized lipid accumula-
ion. Attachment of microbubble contrast agents
re shear dependent (26). This problem, however,
ay be solved with the use of targeting moieties
hat normally act through a “catch bond” (such as
ecombinant PSGL-1 or GP1b) and are able to
roduce capture at high shears. Finally, the com-
lex particle-based nature of ultrasound and the
eed for chemical conjugation of surface target-
ng molecules will necessitate extensive safety
esting by regulatory agencies before any product
ill be considered for clinical use.
ediated Arteriogenesis
d molecular imaging for monocyte alpha5-integrin for the proxi-
chemistry demonstrated alpha5-integrin–positive (red) monocyte
alpha5-integrin–positive monocytes in the ischemic limb whichia-M
oun
isto
t forion, from Behm et al. (31). *p  0.05 versus control.
SM
i
c
m
n
r
r
p
c
m
m
a
d
p
r
i
f
R
L
H
P
R
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 3 , N O . 2 , 2 0 1 0
F E B R U A R Y 2 0 1 0 : 2 0 4 – 1 1
Lindner
Molecular Imaging of Vascular Phenotype
210ummary
any of the key biologic processes responsible for
schemic and/or inflammatory diseases of the myo-
ardium and vascular system are being targeted by
olecular imaging in the hope that unique diag-
ostic and research applications will follow. The
ole of contrast ultrasound will undoubtedly be
elated not only to sensitivity for detecting these
rocesses, but also to practical matters of cost and
onvenience. Evidenced by the scientific achieve-
ents summarized in this review, the diagnosticInfluence of surface charge on capil- sound assessment ofain in the “feasibility” stage where single targeted
gents are tested in animal models of established
isease. The transition to clinical testing will de-
end, not on technical factors, but rather on the
ecognition of situations in which molecular imag-
ng can provide unique information that is critical
or treatment decisions.
eprint requests and correspondence: Dr. Jonathan R.
indner, Cardiovascular Division UHN-62, Oregon
ealth & Science University, 3181 SW Sam Jackson
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